Bile acids (BAs) play critical physiological functions in cholesterol homeostasis, and deregulation of BA metabolism causes cholestatic liver injury. The long noncoding RNA maternally expressed gene 3 (MEG3) was recently shown as a potential tumor suppressor; however, its basic hepatic function remains elusive. Using RNA pull-down with biotin-labeled sense or anti-sense MEG 3RNA followed by mass spectrometry, we identified RNA-binding protein polypyrimidine tract-binding protein 1 (PTBP1) as a MEG3 interacting protein and validated their interaction by RNA immunoprecipitation (RIP). Bioinformatics analysis revealed putative binding sites for PTBP1 within the coding region (CDS) of small heterodimer partner (SHP), a key repressor of BA biosynthesis. Forced expression of MEG3 in hepatocellular carcinoma cells guided and facilitated PTBP1 binding to the Shp CDS, resulting in Shp mRNA decay. Transient overexpression of MEG3 RNA in vivo in mouse liver caused rapid Shp mRNA degradation and cholestatic liver injury, which was accompanied by the disruption of BA homeostasis, elevation of liver enzymes, as well as dysregulation of BA synthetic enzymes and metabolic genes. Interestingly, RNA sequencing coupled with quantitative PCR (qPCR) revealed a drastic induction of MEG3 RNA in Shp 2/2 liver. SHP inhibited MEG3 gene transcription by repressing cAMP response element-binding protein (CREB) transactivation of the MEG3 promoter. In addition, the expression of MEG3 and PTBP1 was activated in human fibrotic and cirrhotic livers. Conclusion: MEG3 causes cholestasis by serving as a guide RNA scaffold to recruit PTBP1 to destabilize Shp mRNA. SHP in turn represses CREB-mediated activation of MEG3 expression in a feedback-regulatory fashion. (HEPATOLOGY 2017;65:604-615).
L ong noncoding RNAs (lncRNAs) are defined as transcripts that exceed 200 nucleotides in length and lack proof of protein coding potential.
(1) lncRNAs mediate physiological and pathological processes and human diseases by regulating the expression of protein-coding genes both transcriptionally and posttranscriptionally. (2) XIST, (3) NEAT1, (4) and HOTAIR (5) can modulate chromatin status via recruiting chromatin-modifying complexes to affect gene transcription. lncRNA-p21 inhibits target mRNA translation via modulating RNA-binding protein HuR. (6) MD1 and HULC are reported to act as microRNA sponges competing with mRNA for micro-RNA binding. (7, 8) OIP5-As1 and GADD7 have been
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shown to control mRNA stability through RNAbinding proteins (RBPs). (9, 10) The lncRNA maternally expressed gene 3 (MEG3) is an imprinted gene maternally expressed from the Dlk1-Gtl2 imprinted locus located at chromosome 14q32.3 in humans. (11) In mice, MEG3 is referred to as gene trap locus 2 (Gtl2) located at chromosome 12. (12) MEG3 has been implicated as a putative tumor suppressor because of its lost expression in several cancers and of its inhibition of cell proliferation. (11) MEG3 regulates genes in the transforming growth factor b signaling pathway via recruitment of polycomb repressive complex 2 (PRC2) in breast cancer cell lines. (13) Although the roles of MEG3 in insulin resistance (14) and liver fibrosis (15) have been reported, the basic hepatic function of MEG3 remains largely unknown.
Bile acids (BAs) as physiological detergents synthesized in the liver facilitate intestinal digestion and absorption of dietary lipid, drugs, and vitamins. (16) BA levels are controlled tightly by a series of enzymes and transporters that are regulated by nuclear receptors and excessive levels of BAs can cause hepatic cholestasis, liver fibrosis, and cancer. (17) More recent major breakthroughs have included the discovery of the role of Gprotein-coupled receptor, (18) fibroblast growth factor, (19) and sphingosine-1-phosphate receptor 2 (20) signaling in bile acid metabolism. Nuclear receptor small heterodimer partner (SHP) is a key inhibitor of BA synthesis (21) via farnesoid X receptor (FXR) (22) and other transcription factor-mediated pathways. (23, 24) SHP exerts its effect by repressing BA synthetic enzymes cholesterol 7a-hydroxylase (CYB7A1) and sterol 12a-hydroxylase (CYB8B1) expression. (25) Shp deletion by gene targeting or its rapid degradation induced by Bcl2 result in elevation of serum BA levels (26) and cholestatic liver fibrosis, (27) suggesting an important role of SHP to maintain normal liver function.
Polypyrimidine tract-binding protein 1 (PTBP1, also known as PTB or hnRNP I) belongs to a subfamily of heterogeneous nuclear ribonucleoproteins (hnRNPs) that control almost all aspects of mRNA metabolism including alternative splicing, polyadenylation, internal ribosome entry site (IRES)-mediated translation initiation and mRNA stability. (28) More and more RBP-lncRNA interactions have been identified recently. To date, two lncRNAs, Pnky and TUNA, have been proven to recruit PTBP1 to regulate neuronal differentiation of neural stem cells (29) and embryonic stem cells. (30) However, limited information is available regarding the function of PTBP1 in metabolic diseases.
In the present study, we identified a novel interaction between MEG3 and PTBP1 through which to modulate hepatic BA metabolism. We showed that MEG3 serves as a guide RNA scaffold to recruit PTBP1 to Shp mRNA, which facilitated Shp mRNA decay. The rapid down-regulation of SHP resulted in activation of Cyp7a1 and Cyp8b1, increased BA synthesis, and cholestatic liver injury. SHP in turn repressed cyclic adenosine monophosphate response element-binding protein (CREB)-mediated activation of MEG3 expression in a feedback regulatory fashion. The reactivation of MEG3 and PTBP1 in human fibrotic and cirrhotic livers highlighted the importance of both genes in human chronic liver diseases. This study elucidates the molecular basis and function of an lncRNA in BA metabolism.
Materials and Methods

MICE
The generation and maintenance of Shp (31, 32) cholic acid (1%) and cholestyramine (2%) feeding, (33) serum and liver collection, (34) serum enzymes, (27) liver histology analysis, (21) hepatocyte isolation and culture, (35) and measurement of serum C4 BA, BA pool size, BA excretion, and BA composition, (27, 36) were performed as described previously. Serum C4 (7a-Hydroxy-4-cholesten-3-one) levels were measured at the Mayo Clinic Immunochemical Core Laboratory. In vivo plasmid transfection was performed using TurboFect in vivo transfection reagent (Thermo Fisher Scientific, Waltham, MA; catalog #R0541). In brief, 50 lg of pcDNA3 or pcDNA3-MEG3 were diluted in 400 lL 5% glucose solution, mixed with 6 lL of in vivo transfection reagent, and incubated for 20 minutes before being injected into WT mice through the tail vein. Serum and liver tissue were collected at day 4 after injection. Experiments were performed and repeated on male mice (age, 8 weeks; n 5 5/group) unless stated otherwise. Protocols for animal use were approved by the Institutional Animal Care and Use Committee at the University of Connecticut.
PLASMIDS, REAGENTS, AND ANTIBODIES
Expression plasmids for SHP, (37) CREB, (38) PTBP1, (39) and MEG3 promoter luciferase reporter (MEG3-Luc) (40) have been described previously. MEG3 expression vector was cloned in our laboratory and confirmed by sequencing. Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), and actinomycin D (ACD) were purchased from Sigma. Bile acid standards were purchased from Steraloids (Newport, RI). Deuterated isotopes used as analytical standards were from C/D/N Isotopes, Inc. (Pointe-Claire, Quebec, Canada). The following antibodies were used for RNA precipitation and western blotting: antibodies against PTBP1 (Thermo Fisher Scientific; catalog #32-4800), b-actin (Sigma, St. Louis, MO; catalog #A-1978), and CREB (Santa Cruz Biotechnology, Santa Cruz, CA; catalog #sc-69374).
CELL CULTURE, TRANSIENT TRANSFECTION, AND LUCIFERASE ASSAY
Human Huh7 (Health Science Research Resources Bank JCRB0403), mouse Hepa-1 (ATCC CRL-1830) and human embryonic kidney (HEK) 293T (ATCC CRL-3216) were maintained as described previously. (37, 41) For ACD treatment, exponentially growing cells were treated with 500 ng/mL ACD for 0, 30, and 60 minutes. Standard methods were used for RNA and protein isolation, complementary DNA synthesis, quantitative PCR (qPCR), western blotting, transient transfection, and luciferase reporter assay. (42, 43) BIOTINYLATED RNA PULL-DOWN ASSAY Biotin-labelled RNA transcripts were synthesized by in vitro transcription with T7 RNA polymerase in the presence of Biotin-11-UTP (Thermo Fisher Scientific). PCR fragments were amplified with forward primers containing T7 RNA polymerase promoter sequences and reverse primers containing T3 RNA polymerase promoter sequences. Purified PCR products were used as a DNA template for in vitro transcription. Whole cell lysates (300-500 lg per sample) were incubated with purified biotinylated RNA probes (10 pmole) for 25 minutes at 308C. RNA-protein complexes were further isolated by streptavidin sepharose high -performance beads (GE Healthcare, Marlborough, MA). The recruited proteins were detected by liquid chromatography-mass spectrometry (LC-MS) or western blotting. Primers containing T7 or T3 promoter sequences used for synthesizing biotinlabeled MEG3, CDS, 3 0 untranslated region (3 0 -UTR) of SHP mRNA, and negative control RNA (complementary to CDS of SHP mRNA) are listed in Supporting Tables S1 and S2. 
NATIVE RNA IMMUNOPRECIPITATION
HUMAN SPECIMENS
The coded human liver specimens were obtained through the Liver Tissue Cell Distribution System (Minneapolis, Minnesota) funded by NIH Contract # HSN276201200017C, as previously described. (27) 
STATISTICAL ANALYSIS
All experiments were performed in triplicate and repeated at least two times. The data presented as the mean values 6 standard error of the mean (SEM). Statistical analysis was carried out using the Student t test for unpaired data to compare the values between the two groups. P < 0.01 was considered statistically significant.
Results
RNA-BINDING PROTEIN PTBP1 SERVES AS A MEG3 BINDING PARTNER
lncRNAs exert their functions by acting as scaffolds to recruit proteins, guides, or decoys for RNA-binding proteins. (44) To identify MEG3-interacting proteins, we conducted a RNA pull-down assay combined with LC-MS. Biotin-labeled sense and antisense (negative control) MEG3RNA probes synthesized by in vitro transcription (Fig. 1A) were incubated with whole cell lysate from HEK293T cells for 20 minutes at 308C. Next, streptavidin beads were used to capture biotin-labeled RNAs and their associated proteins. The RNA-protein complexes were subjected to SDS-PAGE followed by Coomassie Brilliant Blue staining (Fig. 1B) . Compared with antisense MEG3, a distinct band was captured by sense MEG3 and was subjected to LC-MS. The proteins identified by LC-MS (Supporting Table S3 ) were classified for biological function using the PANTHER (protein analysis through evolutionary relationships) method. In biological process classification, the proteins associated with metabolic process and cellular process predominated, whereas the proteins associated with binding and catalytic activity predominated in molecular function classification (Supporting Fig. S1 ). PTBP1 was further analyzed because of its multiple roles in gene expression regulation. (45) Western blotting with anti-PTBP1 antibody confirmed the existence of PTBP1 within MEG3 sense RNA probe pull-down samples (Fig.  1C) . In contrast, PCNA protein was not associated with MEG3 (a negative control).
Because the results of RNA pull-down reflect RNA-protein interaction in vitro, (46) we performed cross-linked an RNA immunoprecipitation assay to detect endogenous association between PTBP1 and MEG3. The results shown in Figure 1D indicate that MEG3 was significantly enriched in samples immunoprecipitated with anti-PTB or anti-PARP1 (another potential MEG3 binding protein) antibodies compared with samples immunoprecipitated with IgG. Taken together, the results demonstrate that the PTBP1 protein bound to MEG3RNA. 
MEG3 ENHANCES PTBP1
RECRUITMENT TO SHP mRNA TO FACILITATE ITS DECAY PTBP1 belongs to a family of ribonuclear proteins (RNPs) known for its role in mRNA metabolism via binding to its target mRNAs. Therefore, we hypothesized that the association between MEG3 and PTBP1 may influence the effect of PTBP1 on its target mRNAs. Several online bioinformatics analysis tools (RBPmap, StarBase v2.0) were used to predict PTBP1 targets. SHP mRNA was predicted to contain potential PTBP1 binding sites within its 3 0 UTR and CDS ( Fig. 2A) . Next, RNA immunoprecipitation assay was performed using anti-PTBP1 and mouse IgG antibodies, respectively, in cells that were transiently expressed with Flag-SHP in the presence or absence of MEG3 coexpression (Fig. 2B) . The results indicate that SHP mRNA was enriched by PTBP1 versus control IgG antibody in HEK293T cells (10-fold) (Fig. 2B, left) . Moreover, this enrichment was significantly increased by MEG3 overexpression (40-fold). Similar results were observed in hepatocyte Hepa-1 (mouse) and Huh7 (human) cells (Fig. 2B, middle and right) . The lesser enrichments of SHP mRNA by PTBP1 and MEG3 in Hepa-1 or Huh7 versus HEK293T were likely attributed by the cells' lower transfection efficiency. Overall, the results indicate that the interaction of MEG3 and PTBP1 facilitated PTBP1 binding to SHP mRNA.
To determine the binding regions of PTBP1 in SHP mRNA, RNA probes containing CDS and 3 0 UTR of SHP mRNA were used for RNA pull-down assays, respectively. Interestingly, the CDS region of SHP mRNA recruited PTBP1 protein in all three cell types, whereas SHP 3 0 UTR also showed binding to PTBP1 protein to a lesser extent in HEK293T cells (Fig. 2C) .
Considering PTBP1 as a crucial regulator of mRNA fate, we further examined the effect of PTBP1 on SHP mRNA stability. ACD was used to block de novo transcription in Hepa-1 or Huh7 cells transfected with MEG3 and PTBP1, alone or in combination. Endogenous SHP mRNA levels were determined at the indicated time points and normalized to GADPH mRNA; the latter has been proven to be stable during ACD treatment. (6) The curves shown in Fig. 2D suggest that overexpression of PTBP1 or MEG3 facilitated SHP mRNA degradation, which were enhanced by their coexpression. Because the results obtained in Hepa-1 and Huh7 cells were consistent, we focused our studies in Huh7 cells in subsequent experiments.
MEG3 AND PTBP1 ACTIVATE Cyp7a1/Cyp8b1 BY DECREASING SHP mRNA
To determine the direct cell autonomous regulation of SHP mRNA by MEG3 and PTBP1, steady state levels of SHP mRNA were further examined in vitro in Huh7 cells. Forced expression of MEG3 (Fig. 3A) or PTBP1 (Fig. 3B ) alone for 48 hours markedly decreased SHP mRNA expression. We repeated the experiment by overexpressing MEG3 and/or PTBP1 for 24 hours. MEG3 and PTBP1 not only inhibited SHP mRNA independently, but also exerted a synergistic effect when coexpressed (Fig. 3C) . As expected, MEG3 and PTBP1, alone or in combination, activated SHP targets Cyp7a1 and Cyp8b1 (Fig. 3D) . Interestingly, FXR mRNA was induced by MEG3 and PTBP1 as well, suggesting that PTBP1 may target FXR. Knockdown of endogenous PTBP1 using specific small interfering RNA (Fig. 3E) blocked MEG3-mediated inhibition of SHP and activation of Cyp8b1 expression (Fig. 3F) , indicating that PTBP1 acted downstream of MEG3 to directly control SHP expression. Overall, the results demonstrated that MEG3 inhibited SHP mRNA expression via a PTBP1-mediated mechanism.
MEG3 INDUCES CHOLESTATIC LIVER INJURY BY DOWNREGULATING SHP EXPRESSION
The critical role of SHP in BA-induced liver injury (27, 36) promoted us to determine the in vivo functionality of MEG3 in BA metabolism. We established liver specific MEG3 overexpressed mouse model by hydrodynamic tail vein injection of control or MEG3 expression vector into C57BL/6J mouse liver.
The exogenously expressed MEG3 RNA was confirmed by qPCR using liver RNA (Fig. 4A, left) . As expected, SHP mRNA was abolished by MEG3 (Fig.  4A , middle, and Supporting Fig. S3 ), and this was accompanied by the up-regulation of Cyp7a1 and Cyp8b1 (Fig. 4A, right) but not other BA regulators and transporters. The hepatic protein level of CYP7A1 was increased in MEG3 mice as well (Fig. 4A, upper  right corner) . The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two classical markers of liver injury, were induced by MEG3 (Fig. 4B) .
Overexpression of MEG3 also induced expression of hepatic genes in various pathways (Fig. 4C) , including Srebp1c (lipid synthesis), F4/80 (inflammation), Gsk-3b (glycogen synthesis), Epcam (stem cell), and Ucp2 (energy metabolism), suggesting a broad disruption of liver metabolic homeostasis. Interestingly, F4/ 80, but not Gsk-3b, Epcam, and Ucp2, was upregulated in Shp 2/2 mouse livers (Supporting Fig. S4 ). The results suggest that the increased expression of Gsk-3b, Epcam, and Ucp2 in MEG3 mice is likely due to a direct effect of MEG3 activation but not an indirect effect of loss of Shp. The ileal expression of apical sodium-bile acid transporter (ASBT), a gene responsible for the initial uptake of bile acids, particularly conjugated bile acids, from the intestine as part of their enterohepatic circulation, was highly elevated in MEG3 mice (Fig. 4C, right) .
Consistent with results observed in Shp 2/2 mice, (26) serum BA and fecal BA excretion were markedly elevated in MEG3 mice (Fig. 4D) . Interestingly, BA pool size remained at similar levels in control and MEG3 mice, despite up-regulation of Cyp7a1 and Cyp8b1. We further measured serum C4 (7a-hydroxy-4-cholesten-3-one) levels, which are indicative of Cyp7a1 activity, (47) and did not observe significant differences between control and MEG3 mice. This may explain the paradoxical increase of Cyp7a1 expression and the unchanged BA pool.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of serum BA composition revealed that the most highly elevated BAs in MEG3 mice were taurine-or glycine-conjugated BAs compared with unconjugated BAs (Fig. 4E, right vs  left) . On the contrary, the secondary BAs including LCA and DCA were reduced in MEG3 mice (Fig.  4E, left) . Histological analysis of liver sections revealed areas of injury (Fig. 4E, red circle) as well as increased glycogen storage (Fig. 4E , black arrow) in MEG3 mice (Fig. 4F) . The retention of high levels of conjugated BAs but low levels of secondary BAs in blood in MEG3 mice suggest a deficiency in BA dehydroxylation and increased reabsorption, thus a disruption of the enterohepatic circulation.
SHP INHIBITS MEG3 EXPRESSION VIA A CREB-DEPENDENT FEEDBACK REGULATION
Similar to other lncRNAs, (27) MEG3 maintained a high level of expression in developmental liver and its expression was shut off in adult liver (Fig. 5A ). To our surprise, RNA sequencing revealed an approximately 95-fold induction of MEG3RNA in Shp 2/2 vs WT liver (Fig. 5B, left) . qPCR confirmed the drastic elevation of MEG3RNA in Shp 2/2 liver collected over a 12-hour light/dark cycle (right). Interestingly, qPCR of MEG3RNA and PTBP1 mRNA in human liver specimens (normal, n 5 6; steatosis, n 5 8; fibrosis, n 5 6; nonalcoholic steatohepatitis cirrhosis, n 5 8). Data are presented as the mean 6 standard error of the mean from triplicate assays. *P < 0.01. **P < 0.001. ***P < 0.0001. (E) Western blot of PTBP1 protein in human liver specimens. Equal amounts of protein from individual specimens were pooled and loaded in duplicate, and the band intensity was quantified. (F) Schematic of MEG3/PTBP1/SHP circuit to modulate BA homeostasis. MEG3 interacts with PTBP1 protein to form an RNA-protein complex. This complex can guide more PTBP1 binding to SHP mRNA to cause its degradation. Loss of SHP results in disruption of BA homeostasis and cholestatic liver injury. In contrast, SHP inhibits CREB-mediated activation of MEG3 expression. The feedback inhibition between MEG3RNA/PTBP1 and SHP mRNA forms a fine-tuned regulation of BA metabolism.
MEG3RNA displayed a diurnal expression pattern that peaked at ZT14. The results suggested SHP as a potential transcriptional repressor of MEG3.
To explore the underlying molecular basis, we identified a CREB binding site in the MEG3 promoter (Supporting Fig. S5 ). Overexpression of CREB but not SREBP1c (neg. con.) induced MEG3RNA in Huh7 cells (Fig. 5C, left) . In addition, MEG3 promoter was activated by CREB, which was inhibited by SHP (middle). Furthermore, CREB protein was induced in Shp 2/2 liver as compared to WT liver (top right). Because loss of Shp in mice elevated serum BA levels, (26, 27) we next determined the effects of BAs on MEG3 expression. Importantly, MEG3RNA and PTBP1 mRNA (Fig. 5D ) and PTBP1 protein (Fig.  5E ) were markedly increased in human fibrosis and nonalcoholic steatohepatitis cirrhosis specimens, suggesting their relevant roles in human liver diseases. Taken together, the results demonstrate that the induction of MEG3 in Shp 2/2 mice was due to a direct loss of SHP inhibition.
Discussion
lncRNAs are emerging as crucial regulators of a variety of human diseases, particularly in cancers. (48) In hepatocellular carcinoma, DANCR induces stemness of tumor cells through reducing CTNNB1 expression. (49) H19 is induced by BA, which may contribute to Bcl2-induced cholestatic liver fibrosis. (27) Lnc-HC exerts its crucial role in cholesterol metabolism by association with hnRNPA2B1 to modulate Cyp7a1 expression. (50) Despite these advances, the lncRNAs involved in BA metabolism have yet to be identified. The present study unveils MEG3 as a novel regulator of BA homeostasis via PTBP1-mediated degradation of SHP mRNA (Fig. 5F) .
lncRNAs often exert their functions through the proteins with which they interact. The first important step to better understand the function of MEG3 is to determine its associated protein in a regulatory network of certain biological processes. To achieve this goal, we identified PTBP1 as an MEG3-interacting protein. Of note, PTBP1 regulates degradation of its target mRNA mainly via binding to a cis-acting element within 3 0 UTR, and PTBP1 binding to a CDS of mature mRNA has not been reported. Interestingly, PTBP1 interacted with CDS of SHP in HEK293T, Huh7, and Hepa-1 cells, but only interacted with 3 0 UTR of SHP in HEK293T, suggesting that the association of PTBP1 with 3 0 UTR of SHP mRNA may be cell type-dependent. Therefore, PTBP1 binding to its target mRNA is likely to be tightly controlled by cellular environments under different physiological conditions.
Recruiting RBPs appears to be a common mechanism among lncRNAs. lncLSTR and gadd7 recruit TDP-43 to control lipid metabolism. (9) We found that MEG3 guided PTBP1 to SHP mRNA to facilitate its decay. MEG3 may use four potential mechanisms to enhance PTBP1 binding to SHP mRNA: (1) MEG3 could recognize SHP mRNA through a conserved RNA element; (2) MEG3 could serve as a protein scaffold to recruit not only PTBP1 but also other proteins to the MEG3-PTBP1 complex as sensors of SHP mRNA; (3) binding to MEG3 may alter PTBP1 protein structure and expose its binding sites in SHP mRNA; and (4) because another typical characteristic of PTBP1 in mRNA regulation is its nucleocytoplasmic shuttling, the association between MEG3 and PTBP1 may facilitate PTBP1 nuclear to cytoplasmic translocation, resulting in enhanced PTBP1 activity in the control of its target mRNA stability. Future studies would be necessary to elucidate how MEG3 guides RBPs to its target mRNAs.
Identifying MEG3 as a SHP target gene is another important finding of this study. Despite intensive efforts aimed at understanding the function of lncRNAs, little is known about how lncRNAs are regulated transcriptionally. In this regard, we demonstrated SHP as a potent transcriptional repressor of MEG3. Interestingly, SHP also served as a transcriptional inhibitor of H19, (27) implicating SHP as a central component of the general transcriptional repressive machinery. (17) We observed an interesting circadian diurnal expression pattern for MEG3, which peaked at the beginning of the dark phase, when SHP expression was the lowest. (34) We speculate that during fasting, the accumulation of glucagon would activate adenylate cyclase in the liver to increase the synthesis of MEG3 via CREB activation. This would allow increased BA synthesis to replace that lost during feeding. Moreover, it has been reported that PTBP1 is phosphorylated by protein kinase A. (39) This might allow the MEG3-PTBP1 complex to be activated and/or move between the nucleus and cytoplasm during fasting. During the feeding cycle, glucagon would be relatively low, allowing Shp to be synthesized to repress BA synthesis.
Taken together, our studies identified the MEG3-PTBP1 axis in fine-tuning BA metabolism by controlling SHP mRNA stability. Our results shed light on the importance of lncRNAs as new regulators of liver function and disease.
